Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety, tolerability, maximum administered dose, and dose
limiting toxicity of SCH 727965 administered as an intravenous infusion on Days 1, 8 and 15
of each 28 day cycle in participants with solid tumors, non Hodgkins lymphoma, multiple
myeloma or chronic lymphocytic leukemia.